Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 12, Alnylam Pharmaceuticals reported its earnings for 2025, with nearly $3 billion in total revenue, which was an 81% increase year-over-year. Q4 was particularly strong, with net product revenue reaching $995 million, fueled by a 151% year-over-year surge in the TTR franchise following the successful launch of Amphotra for ATTR cardiomyopathy. In this quarter, Alnylam also launched ...

Core Insights - Alnylam Pharmaceuticals focuses on RNA interference (RNAi) therapeutics aimed at silencing specific genes related to various diseases, positioning itself competitively alongside peers like BioMarin, Ionis, Sarepta, and Agios [1] Financial Performance - Alnylam has a Return on Invested Capital (ROIC) of 13.74% and a Weighted Average Cost of Capital (WACC) of 5.69%, resulting in a ROIC to WACC ratio of 2.42, indicating effective capital utilization [2][5] - In contrast, Ionis Pharmaceuticals has a ROIC of -9.98% and a WACC of 5.25%, leading to a negative ROIC to WACC ratio of -1.90, while Sarepta and Agios also report negative ratios of -1.04 and -4.91 respectively [3][5] Capital Efficiency - Alnylam's ROIC to WACC ratio of 2.42 positions it as a leader in capital efficiency among its peers, suggesting it is effectively utilizing its capital to generate returns [4][5]

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the best money-making stocks to buy right now. On February 13, Morgan Stanley trimmed the price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $360 from $408 and reiterated an Equal Weight rating, TheFly reported. In a research note, the analyst said that although near-term pressures exist, the preannounced fourth-quarter revenue and reaffirmed 2026 TTR sales guidance reflect increased confidence in the launch. On the same day, RBC Capital al ...

Several positive new analyst notes were the tailwinds pushing the stock of Alnylam Pharmaceuticals (NASDAQ: ALNY) higher on Tuesday. The first day of the holiday-shortened trading week saw Alnylam's share price floating more than 6% higher in late-session trading. A new bull says buy Of these analyses, the one authored by Ilya Zubkov of Freedom Capital Markets appeared to have the greatest impact on Alnylam stock. The pundit upgraded his recommendation on the company to buy from his previous hold, althou ...

Core Viewpoint - Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is currently viewed as a strong investment opportunity despite recent price target reductions by analysts, indicating a positive long-term outlook for the company and its TTR franchise [1][2][3]. Analyst Ratings and Price Targets - Bank of America has lowered its price target for Alnylam from $529 to $462 while maintaining a Buy rating, reflecting a cautious outlook for Q4 2025 [1]. - H.C. Wainwright also reduced its price target from $570 to $510, yet continues to endorse a Buy rating, citing a disciplined approach to near-term growth and margins [2]. - Barclays initiated coverage of Alnylam with an Overweight rating and a price target of $527, part of a broader positive outlook on the biotech sector for 2026 [3]. Company Overview - Alnylam Pharmaceuticals specializes in discovering, developing, and commercializing therapeutics based on ribonucleic acid interference [4].

Core Insights - Alnylam Pharmaceuticals has experienced a significant decline in share price, dropping nearly 40% from its all-time high since October 2025 [1] Company Performance - The decline in Alnylam's stock is attributed to the company's current phase in the biopharma industry, where investor sentiment is heavily influenced by factors beyond clinical trial outcomes [1]

Core Insights - Alnylam Pharmaceuticals reported fourth-quarter 2025 adjusted earnings of $1.25 per share, exceeding the Zacks Consensus Estimate of $1.16, compared to adjusted earnings of 6 cents in the same quarter last year [1] - Total revenues for the quarter were $1.10 billion, falling short of the Zacks Consensus Estimate of $1.14 billion, but representing an 85% year-over-year increase from $593.2 million [2] Financial Performance - Net product revenues reached $994.7 million, marking a 121% increase year over year, driven by strong demand for Amvuttra and other marketed drugs [3] - Net revenues from collaborators were $40.9 million, a 62% decrease from the previous year, primarily due to the absence of revenues from Novartis in the reported quarter [4] - Royalty revenues increased by 73% year over year to $61.4 million [5] Product Performance - Amvuttra generated sales of $826.6 million, up 189% year over year, although it missed the Zacks Consensus Estimate of $837.2 million [8] - Givlaari sales were $86.8 million, reflecting a 34% year-over-year increase and exceeding the Zacks Consensus Estimate of $79.7 million [9] - Oxlumo recorded sales of $49.6 million, a 14% increase year over year, but fell short of the Zacks Consensus Estimate of $55.2 million [9] Guidance and Future Outlook - For 2026, Alnylam expects net product revenues between $4.9 billion and $5.3 billion, indicating a year-over-year growth of 64-77% at constant exchange rates [17] - The company anticipates net revenues from collaborations and royalties to be in the range of $400 million to $500 million, with adjusted R&D and SG&A expenses projected between $2.7 billion and $2.8 billion [17] Overall Assessment - Alnylam's fourth-quarter results were mixed, with earnings surpassing estimates but revenues missing expectations, likely due to high market expectations rather than a decline in demand [18] - The significant year-over-year revenue growth was primarily driven by strong sales of Amvuttra, supported by recent label expansions [19]

Summary of siRNA Industry Insights Industry Overview - The siRNA drug market is projected to reach $50.3 billion by 2040, indicating a significant growth opportunity in the nucleic acid therapy sector, which is gaining traction as a new drug development direction [1][1][1] Key Insights - siRNA drugs offer high efficiency, low toxicity, and long-lasting effects compared to traditional small molecules and biologics, making them a popular choice in new drug development [1][1][1] - The GalNAc liver delivery platform has matured, showing high delivery efficiency and specificity, becoming the standard for liver-targeted siRNA drugs. Notable targets include PCSK9, AGT, Lp(a), and ApoC3, which have demonstrated therapeutic potential [1][1][1] - There is potential for breakthroughs in extrahepatic delivery systems, with early-stage developments in areas such as muscle, CNS, and ocular applications. Alnylam's C16 delivery platform is showing promise in Alzheimer's disease, while Arrowhead and Wave Life Sciences are exploring fat tissue targets [1][1][1] Market Dynamics - Domestic siRNA companies are positioned to capitalize on the demand for new technologies as traditional chronic disease drugs approach the end of their sales lifecycle. Collaborations with multinational corporations (MNCs) are expected to increase, particularly in liver delivery systems [2][2][2] - The industry outlook is optimistic, with domestic siRNA drugs likely to secure partnerships in popular targets like PCSK9 and Lp(a). New demands in weight loss and CNS delivery are further opening up the market as international giants make breakthroughs [2][2][2] Relevant Companies - A-share listed companies: Yuyuan Pharmaceutical, Frontier Biotech, Fuyuan Pharmaceutical, Bibetech, Sunshine Nuohuo, Chengdu Xian Dao - Hong Kong listed companies: Reebio, and upcoming IPOs such as Jingyin Biotech and Bowe Pharmaceutical - Upstream industry chain participants include WuXi AppTec, Lianhua Technology, Aorite, Lanxiao Technology, Nawei Microbiology, and Jiuzhou Pharmaceutical [2][2][2]

Core Insights - Alnylam Pharmaceuticals achieved full-year GAAP profitability in 2025, driven by an 81% year-over-year growth in net product revenues [4] - The TTR franchise generated $858 million in Q4 2025, reflecting a 151% year-over-year increase, primarily due to the U.S. launch of Amvuttra for ATTR cardiomyopathy [4] - Amvuttra has nearly matched tafamidis in new treatment starts by its second full quarter post-launch, indicating a shift in prescribing dynamics [4] Strategic Performance and Platform Evolution - The company launched Cyrillis, a proprietary enzymatic ligation-based manufacturing platform aimed at expanding capacity and reducing costs for RNAi therapeutics [4] - Management attributes commercial success to broad first-line payer access, with over 90% of payers providing coverage without step-through requirements [4] 2026 Guidance and Long-term Strategic Goals - The 2026 TTR revenue guidance is projected between $4.4 billion and $4.7 billion, assuming continued category growth and a mid-single-digit net price decrease in the U.S. [8] - The 2030 strategy aims for a 25% revenue CAGR and 30% non-GAAP operating margins, supported by a pipeline of over 25 clinical programs [4][8] - Planned R&D investment will remain at approximately 30% of revenues to accelerate organic innovation and selectively access external technologies [8] Competitive Dynamics and Pricing Sustainability - Management anticipates a Q1 2026 revenue headwind due to pricing alignment in Germany and annual U.S. insurance reauthorizations [8] - International TTR revenue growth in 2026 is expected to align with 2025, moderated by lower launch pricing for cardiomyopathy in European markets [8] - Collaboration revenue is projected to decline by 38% in 2026 due to a one-time $300 million milestone from the zalesiran program not recurring [8]

Core Viewpoint - Alnylam Pharmaceuticals reported a profitable fourth quarter, yet its stock price declined significantly despite the positive earnings report [1][2]. Financial Performance - The company achieved a net income of $111.5 million, or $0.82 per share, compared to a loss of $83.8 million, or $0.65 per share, in the same quarter last year [2]. - Adjusted earnings per share rose to $1.25 from $0.06, indicating a substantial improvement in profitability [2]. - Total revenues nearly doubled to $1.10 billion from $593.17 million, showcasing strong growth [2]. - Net product revenues increased to $994.7 million from $450.8 million, reflecting robust sales performance [2]. Stock Performance - Alnylam shares fell by 6.54 percent, closing at $300.70, down from a previous close of $321.75 [1]. - The stock traded within a range of $298.00 to $315.51 during the session on Nasdaq, with a trading volume of 552,594 shares, below the average volume of 1,494,936 [1]. Future Projections - For the year 2026, the company projects total net product revenues to be in the range of $4.9 billion to $5.3 billion, indicating optimistic growth expectations [3].